The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...
In December, the U.S.-based National Academy of Sciences published a report classifying myopia, for the first time, as a ...
Paediatric ophthalmologist, Dr Katie Williams, discusses her research exploring factors associated with myopia ...
Every morning – shortly after checking my phone and shortly before brushing my teeth – I pull down my lower eyelids in turn ...
Myopia is the most common eye disease in children ... pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the ...